Axsome Therapeutics (AXSM) said Tuesday that a late-stage trial of AXS-12, a narcolepsy drug candidate, had achieved its primary endpoint of statistically significant reduction in cataplexy attacks.
Treated patients who were switched to placebo had worsened attacks with an increase of 10.29 attacks per week, whereas those who continued AXS-12 treatment saw an increase of 1.32, Axsome said.
The drug also showed statistical significance in improving cognition and overall narcolepsy symptoms, the company said.
Shares of the company were up 2.8% in recent Tuesday premarket activity.
Price: 102.00, Change: +4.50, Percent Change: +4.6
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。